Understanding the population a company serves is important in giving the individual what they want, said Jay Sheehy, senior vice president of product innovation at EmblemHealth. Fact-based information and consumer-oriented solutions are 2 strategies that Sheehy said healthcare companies could deploy to learn more about the consumer and in turn, better engage their customers.
Understanding the population a company serves is important in giving the individual what they want, said Jay Sheehy, senior vice president of product innovation at EmblemHealth. Fact-based information and consumer-oriented solutions are 2 strategies that Sheehy said healthcare companies could deploy to learn more about the consumer and in turn, better engage their customers.
Transcript (slightly modified)
What are some strategies to engage consumer groups that are traditionally more difficult to enroll, such as Hispanics or millennials?
How do you get them more engaged is really understanding what’s important to them and really understanding their needs and doing the research and asking them, having focus groups. We spent a lot of time with different sub segments of the population with employers, with HR directors, with brokers and consultants, trying to really build and that’s sort of a continuous learning process that we need to go to.
But it’s really understanding what’s really important to them. There’s a lot of studies out more recently about, you know, you hear about millennials and they’re so unique. They’re really not that different and a lot of the studies, I know PWC just came out with one that says millennials are really no different than any other generation and what they see is important to them. They may position it a little differently or communicate it differently. So again, getting fact-based information about the populations we serve and really trying to build solutions that will meet their needs are really our primary focus.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More